Announced Fri, 14 Aug, 2026 · 08:42 IST

Gland Pharma appoints Deepak Sapra as new CEO from November 16

Ceo Appointed ExternalManagement Changes View source PDF Explain this filing

GLAND · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+0.0%Reaction day

₹2965.00

prior close

₹2950.40

announcement price

After-mkt

timing

Nifty Smallcap 250market-0.5%+0.5% vs market

Pharmaceuticals peers, median of 166sector-0.4%+0.4% vs sector

On the reaction day the stock moved 0.5 pts more than Nifty Smallcap 250 and 0.4 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+1.3

10m

+1.1

15m

+0.9

30m

+1.1

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+0.0-0.5+0.5-0.4+0.4

Next day

-2.1-0.3-1.8-0.3-1.8

-3.7-0.1-3.6-0.5-3.2

-4.3-0.7-3.5-1.3-3.0

-3.9-0.1-3.8-0.8-3.1

-5.2+0.3-5.4-0.4-4.8

-4.5-0.1-4.4-0.9-3.7

15d

-0.9+0.6-1.5+0.0-0.9

-1.9-2.6+0.7-0.1-1.8

+2.8-2.9+5.7-2.8+5.6

—————

UpDownMarket · Nifty Smallcap 250Sector · Pharmaceuticals peers, median of 166Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Gland Pharma's Board has approved the appointment of Mr. Deepak Sapra as the new Chief Executive Officer, effective November 16, 2026, subject to his acceptance. He brings 27 years of experience, with over 23 years in pharma. He currently heads the API and Services business at Dr. Reddy's Laboratories and is also a Board Member at Aurigene Pharma Services. His background covers global generics, CDMO, APIs, business development and M&A across the US, Europe, Japan and emerging markets.

Likely market impact

External hire of a seasoned pharma leader from Dr. Reddy's signals strategic focus on global growth and portfolio expansion.